Objectives: The main purpose of using a surrogate endpoint is to estimate the treatment effect on the true endpoint sooner than with a true endpoint. Based on a metaregression of historical randomized trials with surrogate and true endpoints, we discuss statistics for applying and evaluating surrogate endpoints.
Methods: We computed statistics from 2 types of linear metaregressions for trial-level data: simple random effects and novel random effects with correlations among estimated treatment effects in trials with more than 2 arms. A key statistic is the estimated intercept of the metaregression line. An intercept that is small or not statistically significant increases confidence when extrapolating to a new treatment because of consistency with a single causal pathway and invariance to labeling of treatments as controls. For a regulator applying the metaregression to a new treatment, a useful statistic is the 95% prediction interval. For a clinical trialist planning a trial of a new treatment, useful statistics are the surrogate threshold effect proportion, the sample size multiplier adjusted for dropouts, and the novel true endpoint advantage.
Results: We illustrate these statistics with surrogate endpoint metaregressions involving antihypertension treatment, breast cancer screening, and colorectal cancer treatment.
Conclusion: Regulators and trialists should consider using these statistics when applying and evaluating surrogate endpoints.
Keywords: Antihypertension treatment; Cancer screening; Cancer treatment; Clinical trials; Meta-analysis; Surrogate endpoints.
Published by Elsevier Inc.